Caris Research
Equity Research By David S. Moskowitz
Click here to sign up for a Caris Research Account
12/17/2009
(ONXX) ONXX - Analyst Day Highlights An Active 2010; Carfilzomib Still Underappreciated – Maintain 2*Above Average Rating
No introduction text is currently available for this report.
12/11/2009
(LLY) LLY - Outlines Trough EPS, Cash Flow and Pipeline Potential Are Reasons To Hold… But Not Buy – Downgrading to 3*/Average, Reducing Target To $34
No introduction text is currently available for this report.
12/08/2009
(EBS) EBS - rPA Award Off The Table For 2009, Biothrax Will Remain The Only Anthrax Vaccine For Several Years – Maintain Buy, Reducing Price Target from $21 to $17
No introduction text is currently available for this report.
12/04/2009
(PRX) PRX - $2.00 Base EPS Plus Near- & Long-Term Upside Potential – Raising Estimates and Price Target, Reiterate 1*/Buy
No introduction text is currently available for this report.
12/01/2009
(PRX) PRX - Focus Anticipated On Brand Drug Business and Cost Guidance At Analyst Day, EPS Upside Remains – Reiterate 1*/Buy
No introduction text is currently available for this report.
11/17/2009
(PRX) PRX-Ultram ER Launch Underway, Raising Estimates and Price Target – Reiterate 1*/Buy, Old: $25, New: $26
No introduction text is currently available for this report.
11/17/2009
(CRXL) CRXL-Hot Property, Well Capitalized, Generating Cash and Building Asset Value – Reiterate 1*/Buy
No introduction text is currently available for this report.
11/13/2009
(ENZN) ENZN - Potential Convertible “Make-Whole” Dilution, Waiting for PEG-SN38 Data, Reducing Rating From 1*/Buy to 2*/Above Average and Price Target From $13 to $11
No introduction text is currently available for this report.
11/10/2009
(ENZN) ENZN - Divesting Specialty Pharma & Contract Mfr. Businesses; Some of The Parts Remain, Biotech Pipeline Is All Upside – Maintain 1*/Buy
No introduction text is currently available for this report.
11/09/2009
(PRX) PRX-Right Time, Right Place, Right Products – Maintain 1*/Buy, $25 Price Target
No introduction text is currently available for this report.
Depending on the investment objectives and financial information specific to your situation, the investments discussed or recommended on this website may or may not be suitable for you. It is your responsibility to consider any investment decision carefully. The information contained on this website should not be construed as advice designed to meet the particular needs of any investor. Past performance is not necessarily indicative of future performance, and does not guarantee future results. The price and/or value of any security noted directly or indirectly on this website may fluctuate adversely to your interests, and/or those of other investors. Caris & Company accepts no liability whatsoever for loss or damage of any sort arising out of use of all or part of any information on this website.